vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $134.9M, roughly 1.8× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 11.1%, a 71.4% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 29.6%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
ANIP vs CTRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $134.9M |
| Net Profit | $27.5M | $111.3M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 82.5% |
| Revenue YoY | 29.6% | 55.1% |
| Net Profit YoY | 367.5% | 113.5% |
| EPS (diluted) | $1.14 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $134.9M | ||
| Q3 25 | $227.8M | $132.4M | ||
| Q2 25 | $211.4M | $112.5M | ||
| Q1 25 | $197.1M | $96.6M | ||
| Q4 24 | $190.6M | $86.9M | ||
| Q3 24 | $148.3M | $77.4M | ||
| Q2 24 | $138.0M | $68.9M | ||
| Q1 24 | $137.4M | $63.1M |
| Q4 25 | $27.5M | $111.3M | ||
| Q3 25 | $26.6M | $74.9M | ||
| Q2 25 | $8.5M | $68.5M | ||
| Q1 25 | $15.7M | $65.8M | ||
| Q4 24 | $-10.3M | $52.1M | ||
| Q3 24 | $-24.2M | $33.4M | ||
| Q2 24 | $-2.3M | $10.8M | ||
| Q1 24 | $18.2M | $28.7M |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 58.1% | ||
| Q2 25 | 6.6% | 61.3% | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 43.0% | ||
| Q2 24 | 3.7% | 15.1% | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 11.1% | 82.5% | ||
| Q3 25 | 11.7% | 56.6% | ||
| Q2 25 | 4.0% | 60.9% | ||
| Q1 25 | 8.0% | 68.1% | ||
| Q4 24 | -5.4% | 60.0% | ||
| Q3 24 | -16.3% | 43.2% | ||
| Q2 24 | -1.7% | 15.6% | ||
| Q1 24 | 13.2% | 45.6% |
| Q4 25 | $1.14 | $0.52 | ||
| Q3 25 | $1.13 | $0.35 | ||
| Q2 25 | $0.36 | $0.35 | ||
| Q1 25 | $0.69 | $0.35 | ||
| Q4 24 | $-0.45 | $0.30 | ||
| Q3 24 | $-1.27 | $0.21 | ||
| Q2 24 | $-0.14 | $0.07 | ||
| Q1 24 | $0.82 | $0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $198.0M |
| Total DebtLower is stronger | — | $894.2M |
| Stockholders' EquityBook value | $540.7M | $4.0B |
| Total Assets | $1.4B | $5.1B |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $198.0M | ||
| Q3 25 | $262.6M | $712.5M | ||
| Q2 25 | $217.8M | $306.1M | ||
| Q1 25 | $149.8M | $26.5M | ||
| Q4 24 | $144.9M | $213.8M | ||
| Q3 24 | $145.0M | $377.1M | ||
| Q2 24 | $240.1M | $495.1M | ||
| Q1 24 | $228.6M | $451.2M |
| Q4 25 | — | $894.2M | ||
| Q3 25 | — | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M | ||
| Q1 24 | — | $595.9M |
| Q4 25 | $540.7M | $4.0B | ||
| Q3 25 | $505.8M | $4.0B | ||
| Q2 25 | $436.8M | $3.3B | ||
| Q1 25 | $418.6M | $2.9B | ||
| Q4 24 | $403.7M | $2.9B | ||
| Q3 24 | $405.9M | $2.4B | ||
| Q2 24 | $455.8M | $1.9B | ||
| Q1 24 | $452.0M | $1.7B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $4.7B | ||
| Q1 25 | $1.3B | $3.9B | ||
| Q4 24 | $1.3B | $3.4B | ||
| Q3 24 | $1.3B | $2.9B | ||
| Q2 24 | $920.8M | $2.7B | ||
| Q1 24 | $914.5M | $2.3B |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $394.0M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $394.0M | ||
| Q3 25 | $44.1M | $100.9M | ||
| Q2 25 | $75.8M | $100.8M | ||
| Q1 25 | $35.0M | $71.4M | ||
| Q4 24 | $15.9M | $244.3M | ||
| Q3 24 | $12.5M | $67.2M | ||
| Q2 24 | $17.4M | $53.0M | ||
| Q1 24 | $18.3M | $48.8M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 3.54× | ||
| Q3 25 | 1.66× | 1.35× | ||
| Q2 25 | 8.87× | 1.47× | ||
| Q1 25 | 2.23× | 1.08× | ||
| Q4 24 | — | 4.68× | ||
| Q3 24 | — | 2.01× | ||
| Q2 24 | — | 4.92× | ||
| Q1 24 | 1.00× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CTRE
Segment breakdown not available.
